Biotechnology company T-Cypher Bio has relocated to a new facility at Abingdon Science Park, Oxford, UK, expanding its footprint to support the development of its pipeline of novel immune engager therapeutics targeting solid tumours and autoimmune disease.
The Barton House site — developed by Kadans Science Partner — has been purpose-built to provide specialist facilities to meet T-Cypher’s operational requirements.
T-Cypher has developed a fully integrated discovery platform and machine learning engine (T-CaTM) to profile the human disease target space and associated T-cell reactivity.
The platform combines proprietary computational and wet-lab systems to identify high copy number targets and enable the development of next-generation therapeutics.
T-Cypher said the relocation would support its future growth as these assets progress toward the clinic.
Abingdon Science Park is a 500,000 sqft life science and innovation campus located within the world-renowned Oxford ecosystem, with T-Cypher now neighbouring companies such as Penlon, Alethio Therapeutics, Sense Bio and Capgemini.
The newly built Barton House provides the firm with 12,000 sqft of purpose-built space — including Containment Level 2 wet laboratories.
Sarah Leonard, CEO, T-Cypher, said: “Moving to Barton House allowed the expansion of our tissue culture space, critical to the in vitro work needed for our IND-enabling studies, as we progress towards the clinic."
Settling into our new home on Abingdon Science Park is an exciting milestone as we look ahead to the future of our company and its vision for building next gen-TCR-based bispecifics in oncology and autoimmune disease.
